Key statistics
On Friday, Oric Pharmaceuticals Inc (4TZ:MUN) closed at 8.55, -32.14% below its 52-week high of 12.60, set on Oct 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.55 |
|---|---|
| High | 8.55 |
| Low | 8.55 |
| Bid | 8.75 |
| Offer | 8.85 |
| Previous close | 9.15 |
| Average volume | 193.00 |
|---|---|
| Shares outstanding | 97.39m |
| Free float | 90.85m |
| P/E (TTM) | -- |
| Market cap | 970.00m USD |
| EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
- ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
- ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
- ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
More ▼
